LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Type May Affect Heart Disease Risk

By LabMedica International staff writers
Posted on 28 Aug 2012
Print article
The blood type of an individual may affect their risk of coronary heart disease (CHD) as people with certain blood types are more likely to develop the disease than are others.

Studies have indicated that ABO blood group might influence plasma lipid level and recently, several genome-wide association studies found that variants at ABO locus were associated with plasma lipid levels and inflammatory markers that were associated with the CHD risk.
Scientists at the Harvard School of Public Health (Boston, MA, USA) examined data covering nearly 90,000 participants aged from 30 to 75 who were followed for 20 years or more in two large well-known American studies that included a cohort of 62,073 women and a cohort of 27,428 adults.

The proportions of men and women in the studies with various blood types were the same as in the general population, and the scientists were able to control for a number of factors that can affect health and heart disease risk, such as age, gender, race, body mass index, diet, smoking, menopause, and medical history.

The blood type AB is the rarest blood type, it occurs in around 7% of Americans, while type O, the most common, occurs in around 43%. Those with blood type AB had a 23% increased risk for heart disease, those with type B had an 11% increased risk, and those with type A had a 5% increased risk, compared to people with type O.

The mechanisms that cause blood type to affect heart disease risk were not investigated, but evidence from other studies gives some clues. Blood type A is linked to higher levels of low-density lipoprotein (LDL) cholesterol, the "bad" cholesterol that clogs up arteries. Blood type AB is linked to inflammation, which can affect how blood vessels work, and people with blood type O have higher levels of a compound that has a beneficial effect on blood flow and clotting.

Lu Qi, MD, PhD, the senior author of the study, said, "It is important to know your blood type, just as it is good to know your cholesterol and blood pressure levels. If you know you are at higher risk, you can reduce the risk by adopting a healthier lifestyle, such as eating right, exercising, and not smoking." Armed with findings like these, health care providers can tailor treatments more effectively. For instance, patients with blood type A could be advised to reduce cholesterol in their diet to lower their risk of heart disease. The study was published on August 14, 2012, in the journal Arteriosclerosis, Thrombosis and Vascular Biology.

Related Links:
Harvard School of Public Health


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.